Shuanglong Liu1, Hongguang Liu, Han Jiang, Yingding Xu, Hong Zhang, Zhen Cheng. 1. Molecular Imaging Program at Stanford, Canary Center at Stanford for Cancer Early Detection, Bio-X Program, Department of Radiology, Stanford University, 1201 Welch Road, Lucas Expansion, P095, Stanford, CA 94305-5344, USA.
Abstract
PURPOSE: One of the major obstacles of the clinical translation of (18)F-labeled arginine-glycine-aspartic acid (RGD) peptides has been the laborious multistep radiosynthesis. In order to facilitate the application of RGD-based positron emission tomography (PET) probes in the clinical setting we investigated in this study the feasibility of using the chelation reaction between Al(18)F and a macrocyclic chelator-conjugated dimeric RGD peptide as a simple one-step (18)F labeling strategy for development of a PET probe for tumor angiogenesis imaging. METHODS: Dimeric cyclic peptide E[c(RGDyK)](2) (RGD(2)) was first conjugated with a macrocyclic chelator, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and the resulting bioconjugate NOTA-RGD(2) was then radiofluorinated via Al(18)F intermediate to synthesize (18)F-AlF-NOTA-RGD(2). Integrin binding affinities of the peptides were assessed by a U87MG cell-based receptor binding assay using (125)I-echistatin as the radioligand. The tumor targeting efficacy and in vivo profile of (18)F-AlF-NOTA-RGD(2) were further evaluated in a subcutaneous U87MG glioblastoma xenograft model by microPET and biodistribution. RESULTS: NOTA-RGD(2) was successfully (18)F-fluorinated with good yield within 40 min using the Al(18)F intermediate. The IC(50) of (19)F-AlF-NOTA-RGD(2) was determined to be 46 ± 4.4 nM. Quantitative microPET studies demonstrated that (18)F-AlF-NOTA-RGD(2) showed high tumor uptake, fast clearance from the body, and good tumor to normal organ ratios. CONCLUSION: NOTA-RGD(2) bioconjugate has been successfully prepared and labeled with Al(18)F in one single step of radiosynthesis. The favorable in vivo performance and the short radiosynthetic route of (18)F-AlF-NOTA-RGD(2) warrant further optimization of the probe and the radiofluorination strategy to accelerate the clinical translation of (18)F-labeled RGD peptides.
PURPOSE: One of the major obstacles of the clinical translation of (18)F-labeled arginine-glycine-aspartic acid (RGD) peptides has been the laborious multistep radiosynthesis. In order to facilitate the application of RGD-based positron emission tomography (PET) probes in the clinical setting we investigated in this study the feasibility of using the chelation reaction between Al(18)F and a macrocyclic chelator-conjugated dimeric RGD peptide as a simple one-step (18)F labeling strategy for development of a PET probe for tumor angiogenesis imaging. METHODS: Dimeric cyclic peptide E[c(RGDyK)](2) (RGD(2)) was first conjugated with a macrocyclic chelator, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and the resulting bioconjugate NOTA-RGD(2) was then radiofluorinated via Al(18)F intermediate to synthesize (18)F-AlF-NOTA-RGD(2). Integrin binding affinities of the peptides were assessed by a U87MG cell-based receptor binding assay using (125)I-echistatin as the radioligand. The tumor targeting efficacy and in vivo profile of (18)F-AlF-NOTA-RGD(2) were further evaluated in a subcutaneous U87MGglioblastoma xenograft model by microPET and biodistribution. RESULTS:NOTA-RGD(2) was successfully (18)F-fluorinated with good yield within 40 min using the Al(18)F intermediate. The IC(50) of (19)F-AlF-NOTA-RGD(2) was determined to be 46 ± 4.4 nM. Quantitative microPET studies demonstrated that (18)F-AlF-NOTA-RGD(2) showed high tumor uptake, fast clearance from the body, and good tumor to normal organ ratios. CONCLUSION:NOTA-RGD(2) bioconjugate has been successfully prepared and labeled with Al(18)F in one single step of radiosynthesis. The favorable in vivo performance and the short radiosynthetic route of (18)F-AlF-NOTA-RGD(2) warrant further optimization of the probe and the radiofluorination strategy to accelerate the clinical translation of (18)F-labeled RGD peptides.
Authors: Xiaoyuan Chen; Ryan Park; Michel Tohme; Anthony H Shahinian; James R Bading; Peter S Conti Journal: Bioconjug Chem Date: 2004 Jan-Feb Impact factor: 4.774
Authors: Ambros J Beer; Roland Haubner; Michael Goebel; Stephan Luderschmidt; Mary E Spilker; Hans-Jürgen Wester; Wolfgang A Weber; Markus Schwaiger Journal: J Nucl Med Date: 2005-08 Impact factor: 10.057
Authors: R Haubner; H J Wester; W A Weber; C Mang; S I Ziegler; S L Goodman; R Senekowitsch-Schmidtke; H Kessler; M Schwaiger Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: Roland Haubner; Wolfgang A Weber; Ambros J Beer; Eugenija Vabuliene; Daniel Reim; Mario Sarbia; Karl-Friedrich Becker; Michael Goebel; Rüdiger Hein; Hans-Jürgen Wester; Horst Kessler; Markus Schwaiger Journal: PLoS Med Date: 2005-03-29 Impact factor: 11.069
Authors: William J McBride; Christopher A D'Souza; Habibe Karacay; Robert M Sharkey; David M Goldenberg Journal: Bioconjug Chem Date: 2012-02-10 Impact factor: 4.774
Authors: Thomas Ebenhan; Isabel Schoeman; Daniel D Rossouw; Anne Grobler; Biljana Marjanovic-Painter; Judith Wagener; Hendrik G Kruger; Mike M Sathekge; Jan Rijn Zeevaart Journal: Mol Imaging Biol Date: 2017-06 Impact factor: 3.488
Authors: Ingrid Dijkgraaf; Samantha Y A Terry; William J McBride; David M Goldenberg; Peter Laverman; Gerben M Franssen; Wim J G Oyen; Otto C Boerman Journal: Contrast Media Mol Imaging Date: 2013 May-Jun Impact factor: 3.161